Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cyclerion Therapeutics stock

Learn how to easily invest in Cyclerion Therapeutics stock.

Cyclerion Therapeutics Inc is a biotechnology business based in the US. Cyclerion Therapeutics shares (CYCN) are listed on the NASDAQ and all prices are listed in US Dollars. Cyclerion Therapeutics employs 32 staff and has a trailing 12-month revenue of around $1.9 million.

How to buy shares in Cyclerion Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CYCN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Cyclerion Therapeutics stock price (NASDAQ: CYCN)

Use our graph to track the performance of CYCN stocks over time.

Cyclerion Therapeutics shares at a glance

Information last updated 2022-09-26.
Latest market close$0.84
52-week range$0.46 - $3.37
50-day moving average $0.88
200-day moving average $1.00
Wall St. target price$9.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.24

Buy Cyclerion Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cyclerion Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyclerion Therapeutics price performance over time

Historical closes compared with the close of $0.84 from 2022-09-27

1 week (2022-09-22) -6.59%
1 month (2022-08-29) 3.70%
3 months (2022-06-29) 52.73%
6 months (2022-03-25) N/A
1 year (2021-09-29) -72.82%
2 years (2020-09-29) -87.81%
3 years (2019-09-27) 13.25
5 years (2017-09-25) N/A

Cyclerion Therapeutics financials

Revenue TTM $1.9 million
Gross profit TTM $-29,749,000
Return on assets TTM -58.63%
Return on equity TTM -106.93%
Profit margin 0%
Book value $0.58
Market capitalisation $36.6 million

TTM: trailing 12 months

Cyclerion Therapeutics share dividends

We're not expecting Cyclerion Therapeutics to pay a dividend over the next 12 months.

Cyclerion Therapeutics share price volatility

Over the last 12 months, Cyclerion Therapeutics's shares have ranged in value from as little as $0.461 up to $3.37. A popular way to gauge a stock's volatility is its "beta".

CYCN.US volatility(beta: 2.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclerion Therapeutics's is 2.215. This would suggest that Cyclerion Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Cyclerion Therapeutics overview

Cyclerion Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

What percentage of Cyclerion Therapeutics is owned by insiders or institutions?
Currently 13.54% of Cyclerion Therapeutics shares are held by insiders and 50.247% by institutions.
How many people work for Cyclerion Therapeutics?
Latest data suggests 32 work at Cyclerion Therapeutics.
When does the fiscal year end for Cyclerion Therapeutics?
Cyclerion Therapeutics's fiscal year ends in December.
Where is Cyclerion Therapeutics based?
Cyclerion Therapeutics's address is: 245 First Street, Cambridge, MA, United States, 02142
What is Cyclerion Therapeutics's ISIN number?
Cyclerion Therapeutics's international securities identification number is: US23255M1053
What is Cyclerion Therapeutics's CUSIP number?
Cyclerion Therapeutics's Committee on Uniform Securities Identification Procedures number is: 23255M105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site